Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
- PMID: 30250260
- PMCID: PMC6432913
- DOI: 10.1038/s41593-018-0235-9
Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
Abstract
A hallmark event in neurodegenerative diseases (NDs) is the misfolding, aggregation, and accumulation of proteins, leading to cellular dysfunction, loss of synaptic connections, and brain damage. Despite the involvement of distinct proteins in different NDs, the process of protein misfolding and aggregation is remarkably similar. A recent breakthrough in the field was the discovery that misfolded protein aggregates can self-propagate through seeding and spread the pathological abnormalities between cells and tissues in a manner akin to the behavior of infectious prions in prion diseases. This discovery has vast implications for understanding the mechanisms involved in the initiation and progression of NDs, as well as for the design of novel strategies for treatment and diagnosis. In this Review, we provide a critical discussion of the role of protein misfolding and aggregation in NDs. Commonalities and differences between distinct protein aggregates will be highlighted, in addition to evidence supporting the hypothesis that misfolded aggregates can be transmissible by the prion principle. We will also describe the molecular basis and implications for prion-like conformational strains, cross-interaction between different misfolded proteins in the brain, and how these concepts can be applied to the development of novel strategies for therapy and diagnosis.
Conflict of interest statement
Competing interests
C.S. is the inventor of the PMCA technology and is currently the Founder, Chief Scientific Officer, and major shareholder of Amprion Inc., a biotech company aiming to develop PMCA and RT-QuIC seeding amplification assays for diagnosis of neurodegenerative diseases.
Figures





Similar articles
-
Proteinopathies: Deciphering Physiology and Mechanisms to Develop Effective Therapies for Neurodegenerative Diseases.Mol Neurobiol. 2022 Dec;59(12):7513-7540. doi: 10.1007/s12035-022-03042-8. Epub 2022 Oct 7. Mol Neurobiol. 2022. PMID: 36205914 Review.
-
Protein misfolding and neurodegeneration.Arch Neurol. 2008 Feb;65(2):184-9. doi: 10.1001/archneurol.2007.56. Arch Neurol. 2008. PMID: 18268186 Review.
-
[Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].Brain Nerve. 2012 Jun;64(6):665-74. Brain Nerve. 2012. PMID: 22647474 Review. Japanese.
-
The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases.J Cell Biol. 2017 Sep 4;216(9):2633-2644. doi: 10.1083/jcb.201701047. Epub 2017 Jul 19. J Cell Biol. 2017. PMID: 28724527 Free PMC article. Review.
-
Attempt to Untangle the Prion-Like Misfolding Mechanism for Neurodegenerative Diseases.Int J Mol Sci. 2018 Oct 9;19(10):3081. doi: 10.3390/ijms19103081. Int J Mol Sci. 2018. PMID: 30304819 Free PMC article. Review.
Cited by
-
Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer's disease.Transl Neurodegener. 2021 Jun 8;10(1):18. doi: 10.1186/s40035-021-00244-3. Transl Neurodegener. 2021. PMID: 34099032 Free PMC article.
-
Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.Ann Neurol. 2020 Sep;88(3):503-512. doi: 10.1002/ana.25824. Epub 2020 Aug 1. Ann Neurol. 2020. PMID: 32557811 Free PMC article.
-
Role of ARK5 in cancer and other diseases (Review).Exp Ther Med. 2021 Jul;22(1):697. doi: 10.3892/etm.2021.10129. Epub 2021 May 2. Exp Ther Med. 2021. PMID: 33986861 Free PMC article. Review.
-
Risk of Neurodegenerative Diseases in Elderly Koreans with an Initial Diagnosis of Type 2 Diabetes: A Nationwide Retrospective Cohort Study.J Diabetes Res. 2023 Nov 8;2023:7887792. doi: 10.1155/2023/7887792. eCollection 2023. J Diabetes Res. 2023. PMID: 38020200 Free PMC article.
-
Insulin-like growth factor 2 (IGF2) protects against Huntington's disease through the extracellular disposal of protein aggregates.Acta Neuropathol. 2020 Nov;140(5):737-764. doi: 10.1007/s00401-020-02183-1. Epub 2020 Jul 8. Acta Neuropathol. 2020. PMID: 32642868 Free PMC article.
References
-
- Ross CA & Poirier MA Protein aggregation and neurodegenerative disease. Nat. Med 10(Suppl), S10–S17 (2004). - PubMed
-
- Soto C Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci 4, 49–60 (2003). - PubMed
-
- Goedert M Neurodegeneration. Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein. Science 349, 1255555 (2015). - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical